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Case presentation
A 28-year-old man was adniitted to the Second Propedeutic Depart-
ment of Medicine at the Aristotelian University of Thessaloniki for
evaluation of the nephrotic syndrome. The patient was in excellent
health until 2 years before admission, when he began to experience
episodes of pleuritic chest pain that spread to the abdominal wall and to
the back. The pain lasted 2 to 3 days with intervals of 10 to 30 days
between attacks; it was intense and necessitated analgesics., usually
aspirin, for relief. Low-grade fever had been documented during these
episodes. Five months prior to admission, the patient had had a
laparotomy at another hospital for suspected acute appendicitis hut
appendicitis was not found. Shortly after the operation, the patient
developed edema, and proteinuria, up to fig/day, was discovered; renal
function was normal. Prednisone, administered in a dose of 50 to 100 mg
on alternate days, produced no improvement. One month prior to
admission, a renal biopsy revealed amyloidosis (Figs. I and 2). Diuret-
ics and a low-salt, high-protein diet were prescribed, but the edema did
not improve.
The patient's family originated in Asia Minor and his sister already
had been diagnosed in this hospital as having familial Mediterranean
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fever. She had no clinical evidence of nephropathy; her painful attacks
had responded satisfactorily to colchicine.
On admission the patient complained of anorexia and a weight loss of
10 kg. Physical examination revealed the following: blood pressure,
120/80mm Hg; pulse, 80; respirations, 16; and temperature 36.8° C. The
head, eyes, ears, nose, and throat were unremarkable. The chest was
clear to auscultation and percussion. The cardiac examination and
peripheral pulses were normal. The abdominal and rectal examinations
were unremarkable. Edema was present in the presacral area and below
the knees. The neurologic examination was within normal limits. No
skin rashes or other lesions were present.
Laboratory findings disclosed the following: hemoglobin, 14 g/dl;
white blood cell count, 9400/mm3 with a normal differential; platelets,
200,000/mm1: serum creatinine, I mg/dl; BUN, IS mg/dl; serum sodium,
138 mEq/Iiter; serum potassium, 3.8 mEq/Iiter; total carbon dioxide
content, 26 mmol/liter; serum protein, 5.1 gldl; serum albumin, 2.8 g/dl;
serum cholesterol, 400 mg/dl; serum calcium, 9.5 mgldl; serum phos-
phorus, 3.8 mgldl; serum uric acid, 5.1 mg/dl. Serum glutamic-oxaloace-
tic transaminase (SGOT) and serum gtutamic-pyruvic transaminase
(SGPT) were normal. Fasting and 2-hour postprandial blood sugar
concentrations were normal. An antinuclear antibody test and rheuma-
toid factor were negative. The 24-hour urinary protein excretion was 6.5
and 7.2 g in two consecutive collections. An intravenous urogram
revealed kidneys of normal size with prompt bilateral function and no
evidence of obstruction.
Renal amyloidosis secondary to familial Mediterranean fever was
diagnosed, and the patient was treated with a low-salt, high-protein
diet, 2 mg of colchicine, 200 mg of spironolactone, and 80 mg of
furosemide or 100 mg of ethacrynic acid daily.
Two months later the patient had ankle edema but no further attacks
of pain. The dose of colchicine was increased to 3 mg daily; however,
because the patient began to have 3 or 4 bowel movements per day, the
dose was subsequently reduced to 1.5 mg daily. By the eighth month of
treatment, proteinuria had declined to less than 2 g/day. Diuretic
treatment was discontinued, and a normal diet was prescribed. Over the
subsequent 3 years, protein excretion ranged from 0.5 to 1.0 g/day. The
patient's wife delivered a normal child during this interval. Four years
after diagnosis, the dose of cotchicine was reduced to I mg daily; soon
thereafter, it was decreased to 0.5 mg daily because the patient was
planning to father a second child.
Approximately 4.5 years after diagnosis, the physical examination
was normal. Urinalysis revealed: specific gravity, 1.022; pH, 6; protein,
2+; no glucose: 5 to 8 white blood cells per high-power field; no red
cells or casts were present. Serum protein electrophoresis showed the
following: albumin, 61%; globulins, a1, 2%; &3, 7%; I, 17%; -y, 13%.
Serum concentrations of immunoglobulins were: IgG, 680 mg/dl tnor-
mal, 80t) to 2000 mg/dl); IgA, 157 mg/dl (normal, 150 to 450 mg/dl); and
1gM, 194 mg/dl (normal, 50 to 200 mg/dl). Serum immune complexes
were 0.061% O.D. (optical density) (normal, 0.075 0.06% 0.1).).
Serum C3 concentration was 98 mg/dI (normal, 60 to 120 mg/dI); the C4
was 894 mg/dl (normal, 200 to 800 mg/dl). Assays for antinuclear, anti-
DNA, and antimitochondrial antibodies all were negative.
676
The Nep/tro/ogy Fortan is designcd to relate the princi-
ples of basic science to clinical problems in nephrology.
Editors
JORDAN J. COHEN
JOHN T. HARRINCTON
JEROME P. KASSIRER
Managing Editor
CHERYL J. ZLJSMAN
New England Medical Center
Tu/ts Unis'crsitv School of Medicine
Boston, Massaehasetts
Figs. 1 and 2. Firs! biopsy (1974) showing
fair/v well preserved renal parenchyma with
moderate amy/aid deposits in the glomeruli
and the arterial wall.
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Approximately 5 years after initiation of treatment, the patient was
hospitalized for reevaluation. His general condition was excellent;
blood pressure was normal and there was no peripheral edema. He
continued to take only 0.5 mg of colchicine daily; he had been free of
painful attacks. The laboratory findings revealed: hematocrit, 50%;
white blood cell count, 8900/mm3 with a normal differential; platelets,
200,000/mm3; erythrocyte sedimentation rate, 30 mm/hr; serum creati
nine. 1.3 mg/dl; BUN, 37 mg/dl; serum sodium, 142 mEq/liter; serum
potassium, 4.8 mEq/liter; blood sugar, 68 mg/dl; SGOT and SGPT,
normal; serum cholesterol, 197 mg/dl; serum protein, 6.2 g/dl; serum
albumin, 3.7 g/dl. The 24-hour urinary protein excretion was 1.8 and 1.0
g in two consecutive collections. A second percutaneous renal biopsy
was performed (Figs. 3 and 4), which will be discussed later.
Discussion
DR. PANAGIOTIS METAXAS (Professor of Medicine and
Chairman, Second Department of Propedeutic Medicine, Uni
versity of Thessaloniki Medical School, Physician-in-Chief,
Agia Sophia Hospital, Thessaloniki, Greece): Our patient suf-
fered his first attack of severe pleurodynia at age 26. For the
next 2 years, he experienced frequent abdominal pain and
paroxysm in the intercostal muscles; these attacks usually were
accompanied by low-grade fever that lasted 2 to 3 days. He then
underwent an exploratory laparotomy and appendectomy., and
during that hospitalization, moderate proteinuria was first de-
tected. The development of ankle edema and the finding of
heavy proteinuria prompted performance of a renal biopsy that
revealed moderately severe renal amyloidosis. One month after
biopsy, he was first admitted to our hospital. We diagnosed
familial Mediterranean fever (FMF) on the basis of the positive
family history, his Asia Minor origin, and clinical and laboi'a-
tory studies that excluded other diseases known to cause renal
amyloidosis.
A'
c
V
Familial Mediterranean fever was clearly established as a
nosologic entity more than 20 years ago by Heller and cowork-
ers [1]. However, sporadic cases of the disease had been
described previously under various eponyms [2—6]. Although
the disease continues to attract the interest of many investiga-
tors [7], the cause of the disease remains unknown.
Familial Mediterranean fever is characterized by a Mediterra-
nean geographic distribution, genetic transmission in an autoso-
mal recessive fashion, and periodic attacks that remit spontane-
ously. it is also characterized by the frequent development of
amyloidosis in which the kidney is the organ predominantly
affected. In 1972, a new feature of the disease was discovered,
namely, the complete prevention or marked reduction in the
frequency and severity of attacks of pain by the long-term
administration of colchicine [8].
The disease is diagnosed by established clinical criteria
(Table 1) and by the presence of associated, but not specific,
laboratory findings (Table 2). A significant fraction of the
population of Northern Greece is of Asia Minor origin; thus,
patients with FMF are not rare in our region. In the patient we
are discussing today, we were much aided in our diagnosis
because we already had diagnosed FMF in the patient's sister.
Moreover, renal amyloidosis had been documented histologi-
cally before we examined the patient. Even in the absence of
the renal biopsy, however, the finding of heavy proteinuria and
the frequency with which renal amyloidosis complicates FME
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Figs. 3 and 4. Second biopsy (1980), showing
heavy amyloid deposits in the glomeruli,
mainly in the mesangium, producing a lobu-
lar pattern and a double contour effect, and
leading to glomerular obsolesence with par-
tial tubular atrophy.
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would have made such a diagnosis a virtual certainty [9, 101.
The incidence of amyloidosis in patients with FMF appears to
be markedly affected by ethnic background. An incidence of
60% has been recorded in Turks [10], approximately 40% iLn
Sephardic Jews [11], and lower rates in Ashkenazic Jews and
Armenians [9, 12—141. Of 9 consecutive patients with FMF in
Northern Greece, 2 had renal amyloidosis when first examined
[15].
Proteinuria not due to amyloidosis has been described in
patients with FMF [9, 13, 14, 161. At present, therefore, a
definitive diagnosis of amyloidosis in FMF requires histologic
evidence. Derosena, Koss, and Pirani, using electron microsco-
py, reported the presence of amyloid fibrils in the urinary
sediment of a patient with renal amyloid [17]. This procedure
would, of course, provide a simple technique for diagnosing the
disease but, unfortunately, this finding has not been confirmed
[18]. Gingival or rectal biopsies, if they include samples from
submucosal layers, are positive for amyloidosis in about 80% of
patients; therefore, renal biopsy may not be necessary. In
theory, the diffusely infiltrated amyloid kidney, having an
altered consistency and elasticity as well as extensive involve-
ment of the arterial and arteriolar walls, could be exceptionally
prone to bleed after renal biopsy. Indeed, this patient experi-
enced hematuria that lasted for 4 days after the second biopsy.
In practice, however, renal biopsy in patients with amyloidoss
has not caused special problems or complications [19—211,
Renal biopsy should be preceded by a thorough investigation of
blood coagulation, because hemostatic defects such as Factor X
deficiency occasionally have been described in patients with
amyloidosis [22—26]. Blood coagulation in this patient remained
normal with the exception of a mild but definite inhibition of
platelet aggregation induced by collagen. Spontaneous pen-
nephric bleeding due to microaneurysms of the renal vessels in
FMF-associated renal amyloidosis has been described; Dor et
al have reported 3 such patients [27].
At this point, I would like to ask Dr. Gavrielides to present
the findings of the first renal biopsy of our patient.
DR. KLIMIs GAVRIELIDES (Department of Pathology, Thea-
genion Medical Institute, Thessaloniki, Greece): The renal
parenchyma, which was satisfactorily preserved, contained 16
glomeruli, convoluted and collecting tubules, and a delicate
stroma. Amyloid, present in relatively small amounts in the
arterial and arteriolar wall, was quite obvious along the capiF-
lary wall of the glomerular loops (Figs. 1 and 2).
DR. METAXAS: I should add that our patient had no evidence
of amyloid involvement of other organs. He had no hepatomeg-
aly or splenomegaly. Clinical and laboratory investigation did
not reveal malabsorption. Thyroid and adrenal function were
intact. The cardiac echogram and the electrocardiogram were
normal. These negative findings are consistent with the obser-
vation that patients with amyloidosis complicating FMF only
rarely manifest evidence of intestinal, endocrine, or cardiac
involvement [14, 28—30]. Apparently, the extracellular accumu-
lation of amyloid in such sites does not produce local distur-
bances or functional problems until a far advanced stage of
involvement is reached. For example, Berlyne and coworkers
found normal adrenal cortical function in patients undergoing
hemodialysis who had renal amyloidosis [28].
The problem, when the patient under discussion was first
examined several years ago, was how to proceed with therapy.
Table I. Diagnostic criteria for FMF
Brief attacks of fever (self-limited)
Brief attacks of pleuritic and/or abdominal pain
Genetic and geographic predisposition
Positive family history
Renal amyloidosis
Therapeutic effect of colchicine
Negative investigation for other causes of fever and serositis
Table 2. Nonspecific laboratory findings in FMF
Leukocytosis, neutrophilia
Increased erythrocyte sedimentation rate
Increased plasma fibrinogen
Positive C-reactive protein
Increased SAA protein
The prognosis appeared grim. Confident that the amyloidosis
was secondary to the FMF, we administered coichicine, which
already had been shown to produce impressive results in
controlling the typical periodic attacks of FMF [8]. We adminis-
tered an increasing dose that eventually reached the level of 1
mg three times daily. The clinical and laboratory course of this
patient over the subsequent 5 years has been instructive and
gratifying. The painful crises disappeared; proteinuria started to
decrease by 8 months, and by 18 months the peripheral edema
had resolved and diuretic administration was discontinued.
Over the subsequent 3 years, urinary protein excretion ranged
from 0.5 to 1.0 g/24 hours. The patient has returned to full
employment, has a normal, 2.5-year-old child, and his wife
currently is pregnant. We should note, however, that over the
last 6 months, protein excretion has increased to as high as 1.8
g/24 hours, and the serum creatinine has risen from 0.8 to 1.0
mg/dl to 1.3 mg/dl. We also should note that the patient himself
decreased the dose of colchicine over the last 18 months to 0.5
mg daily because he was planning to father a second child. He
has remained free of painful attacks, however.
I would now like to ask Dr. Gavrielides to present the
findings of the second renal biopsy, which was obtained more
than 5 years after colchicine therapy was begun.
DR. GAVRIELIDES: The glomeruli were larger than usual and
showed a lobular pattern, which resulted from eosinophilic
deposits in the mesangium and along the capillary wall. These
deposits had caused variable obliteration of the capillary lumen
and had led to partial or complete sclerosis (obsolescence) of
three of the glomeruli. In several instances, splitting of the
basement membrane was present. Silver-methenamine impreg-
nation revealed a double-contour configuration of the capillary
wall. The convoluted tubules showed small foci of atrophy and
basement membrane thickening, whereas some of the collecting
tubules were dilated and contained hyaline casts. The stroma
was increased and scierosed in places but showed no inflarnma-
tory infiltrate. Walls of the arteries and arterioles were irregu-
larly thickened, but the juxtaglomerular apparatuses were not
prominent. The Congo red stain was strongly positive in the
glomeruli, the arterial wall, and the tubules both under light
microscopy and under polarized light.
There are both quantitative and qualitative difference:; be-
tween the first and second biopsies. In the second, the amyloid
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deposits are more prominent and caused glomerular obsoles-
cence and tubular atrophy with stromal increase; they also
seem to be located mainly within the mesangium, producing a
prominent lobulation of the glomeruli.
DR. METAXAS: The findings of the second biopsy did not
totally surprise us because it is well known that amyloid,
especially renal amyloid, is very resistant to proteolysis and
phagocytosis. Experimental studies and clinical experience,
however, have documented regression of amyloid deposits [31—
33]. Triger and Joekes [34] and WaldenstrOm [351 have present-
ed isolated case reports in which renal amyloidosis resolved
both clinically and histologically following resolution of the
primary disease. In general, however, renal histologic abnor-
malities persist despite clinical improvement [36, 37].
The beneficial influence of colchicine on this patient's
nephropathy is consistent with clinical and experimental obser-
vations. Remission of the nephrotic syndrome and stabilization
of renal function have been described in a number of patients
[38—40]. To our knowledge, however, in no patient has a second
renal biopsy been obtained to judge the effectiveness of colchi-
cine therapy on the histology of the kidney. Using rectal biopsy,
Ravid and colleagues have observed partial resolution of amy-
loidosis [40]. Despite the histologic findings in the present
patient, we believe that the administration of colchicine was
beneficial because of the observed changes in this patient's
urinary protein excretion. We have observed a similar clinical
response in another patient after long-term administration of
cotchicine. Furthermore, it appears that coichicine may prevent
the development of amyloidosis in FMF, According to Gafni,
Sohar, and Zemer, 3 years after the wide adoption in Israel of
the policy of administering colchicine to patients with FMF, the
number of patients who manifest renal amyloidosis has de-
creased significantly. Whereas previously these investigators
encountered approximately 6 to 12 new patients with amyloid-
osis per year, they have seen only one patient since the
widespread use of colehicine was accepted [19]. According to
these authors, colchicine did not help patients who already
were uremic. In the near future we surely will have more
observations on the therapeutic role of colchicine in patients
with established renal amyloidosis and FMF and, possibly, in
patients with other forms of secondary amyloidosis,
The ability of colchicine to prevent the experimental amyloid-
osis that occurs following repeated injections of casein is well
known [31—33]. Colchicine has an antimitotic effect on a wide
variety of cells implicated in the production of SAA, the serum
protein currently considered the circulating precursor of AA
protein, which forms amyloid deposits in FMF and other
secondary amyloidoses [41—43].
The potential therapeutic role of colchicine in the renal
amyloidosis of FMF can be assessed only when viewed in the
context of the natural history of the disease. Renal amyloidosis,
regardless of its cause, generally is considered one of the most
malignant renal maladies because it rapidly and inexorably
progresses to end-stage renal failure. Cases of spontaneous
remission are extremely scarce [44, 45]. As shown in Table 3,
the renal amyloidosis of FMF progresses according to a fairly
predictable pattern [19]. During the initial preclinical phase,
investigation of kidney function and urinalysis are, by defini-
tion, unrevealing. Notwithstanding, even in this phase histolog-
ic examinations can reveal amyloid in various organs; in the
Table 3. Natural history of renal amyloidosis in FMF
Phases Characteristics
Duration
(years)
Range
(years)
Preclinical None unknown
Proteinuric Mild proleinuria 3—4 2—10
Nephrotic Full nephrotic syndrome 1—2 0.5—5
Uremic Progressive chronic renal failure 1—1.5 0.5—6
Hemodialysis FMF attacks ameliorated?
Amyloidosis of other organs
Posttransplant Exacerbation of FMF attacks
Recurrent amyloidosis in graft
case of the kidney, amyloid is deposited in arteries and in the
arterioles of the glomerulus. It is difficult to quantify the
duration of this phase, but it probably varies considerably.
The preclinical phase is followed by a proreinuric phase,
during which moderate proteinuria is discovered, often inciden-
tally; once detected, the proteinuria is usually persistent. The
urinary sediment is characteristically nonspecific. Occasionally
the patient manifests microscopic or macroscopic hematuria
[14, 46]. Histologically, renal amyloidosis involves the glomeru-
lar capillaries in a segmental fashion; the degree of involvement
varies substantially among glomeruli. Electron microscopy
reveals that the amyloid fibrils are deposited in the form of
nodules on the endothelial side of the basement membrane.
However, intramembranous amyloid deposits also are present.
as are deposits on the epithelial side of the membrane; fusion of
foot processes is also noted, The proteinuric phase lasts from 3
to 4 years, the range being 2 to 10 years.
In 60% to 80% of patients, a nephroric phase characterized by
heavy proteinuria and edema follows the proteinuric phase.
Proteinuria is usually impressively severe and nonselective.
Management of the hypoalbuminemia and edema is often
difficult. The persistent reduction in blood volume, often com-
plicated by diuretic-induced volume contraction, is thought to
be responsible for the frequent development of renal vein
thromboses. Such thrombosis starts from the small branches of
the renal vein and often progresses insidiously and gradually.
This complication has been observed in as many as 39% of
patients [47].
Progression from the nephrotic phase to the subsequent
uremic phase takes 1 to 2 years; the range is 0.5 to 5.0 years.
During this phase, proteinuria subsides but substantial protein
losses persist relative to the decrease in GFR. Hypertension is
often absent; however, a substantial number of patients have
hypertension during the final stage of the disease [33, 48, 49].
End-stage renal failure ensues in 12 to 18 months; the range is 6
months to 6 years. At this stage, fibrotic scarring of the
glomeruli dominates the histologic picture and the kidneys are
shrunken.
Over the last several years, some patients with FMF and
renal amyloidosis have been managed with chronic hemodialy-
sis and renal transplantation [28, 50—56]. Hemodialyzed pa-
tients with FMF and renal amyloidosis, however, have a
survival rate 20% less than that of the general population of
patients undergoing chronic dialysis [51]. Rubinger, Fried-
laender, and Popovtzer have presented evidence suggesting
that during hemodialysis, the clinical attacks of FMF are
ameliorated [52]. Clinical problems secondary to amyloid inva-
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sion of other organs such as the small intestine, thyroid gland,
and heart have been observed.
Observations on patients with FMF-associated renal amy-
loidosis who have undergone transplantation are few. An
exacerbation in the number of attacks of FMF has been
described [52], as well as amyloid deposition in the graft after 6
months to 5 years 150, 53, 54, 57]. In the few reported patients,
the grafts continued to function satisfactorily and the amyloid
deposition involved only the interlobular arteries. These pa-
tients should not be deprived of hemodialysis and renal trans-
plantation. Of course, colchicine should be administered pro-
phylactically to the transplanted patients both to control the
attacks of FMF and possibly to prevent amyloid deposition in
the kidney and other organs.
Questions and answers
DR. NIc0LA0s E. MADIAS (Renal Service, NEMC, Boston,
Mass.): Thank you for this fine presentation. I should like to
open the question-and-answer period by referring to those
patients with nephrotic syndrome and renal amyloidosis sec-
ondary to chronic inflammatory processes other than FMF. In
these patients, do the nephrotic syndrome and the renal amy-
bid deposits resolve once the inflammatory condition is either
eliminated or suppressed?
DR. METAXAS: The information available on this point is
quite limited. However, early work by Waldenström [35] and
subsequent work by others [33, 35, 36, 58] suggests that, if the
underlying inflammatory process is treated satisfactorily, signi1
icant clinical resolution of the renal amyloidosis may occur.
That is, improvement or complete regression of the nephrotic
syndrome and improvement in renal function are possible.
Even though this clinical improvement is sometimes accompa-
nied by partial resolution of renal amyloid deposits, the deposits
generally persist and occasionally they become even more
prominent. As a rule, the clinical resolution is not reflected in
resolution of the renal amyloidosis. Again, in contrast to other
organs (e.g., liver, spleen, lymph nodes, skin), which appear to
be much more amenable to complete resolution of the amyloid
deposits, the kidneys manifest an extraordinary resistance to
such regression. Moreover, if the renal amyloidosis is relatively
advanced, successful treatment of the underlying inflammatory
condition does not appear to ameliorate the renal manifesta-
tions. I can recall 3 patients with advanced secondary amyloi-
dosis due to chronic osteomyelitis in whom aggressive treat-
ment of the osteomyelitis culminating in amputation did not
interrupt the deterioration of renal function.
DR. MADIAS: Certain aspects of the histopathologic evolution
in the patient presented today are highly reminiscent of a report
of renal amyloidosis consequent to extensive infected burns
[59]. In that case, serial biopsies over a 6-year period revealed
that resolution of the nephrotic syndrome was attended by
substantial morphologic regression of the amyloid deposits. In
the latest biopsy, however, 4 of the 12 glomeruli were obsolete.
As in today's patient, irregular thickening of the glomerular
basement membrane and formation of a double capillary wall
contour were noted, the latter reflecting deposition of basement
membrane-like material encasing the amyloid deposits. These
developments were thought to represent a form of scarring
consequent to the amyloid deposition.
DR. ACHILLES TOURKANTONIS (Profrssor of Medicine and
Chairman, A' Department of Internal Medicine, Univ. of
Thessaloniki Medical School, Physician-in-Chief, AHEPA Hos-
pital, Thessaloniki): We currently are caring for 3 patients with
FMF. In these patients, colchicine at a dose of 0.5 mg daily has
been effective in eliminating the febrile and painful crises. The
first patient is free of evidence of nephropathy over a 4-year
period of follow-up. The second patient has developed renal
amyloidosis that has progressed to moderately severe renal
insufficiency over a 2-year period. The third patient was discov-
ered in 1970 and within 4 years advanced to end-stage renal
disease. A renal transplant was performed but, unfortunately, 6
months later renal failure recurred, A biopsy revealed amyloid
deposition in the renal allograft; subsequently, the graft was
removed and the patient was returned to chronic hemodiatysis.
I have three questions: (1) Are the number and/or the severity
of the attacks of FMF related to the development of amyloido-
sis? (2) Is there a need for daily doses of colchicine higher than
0.5 mg, a dose that usually appears effective in controlling the
crises of FMF? (3) Do you know of any experience with the
administration of dimethyl sulfoxide (DMSO) in renal amyloi-
dosis secondary to FMF?
DR. METAXAS: In regard to your first question, there does not
appear to be a relationship between the number and intensity of
the attacks of FMF and the subsequent development of amy-
loidosis. The Israelis have described two FMF phenotypes: in
phenotype I, the attacks of fever and serositis appear first and
amyloidosis appears later if at all; in phenotype II, amyboidosis
is the first manifestation of the disease. These observations
attest to a lack of correlation between clinical attacks and the
development of amyloidosis. Our experience has been quite
similar. Patients with frequent and severe attacks, such as the
sister of today's patient, often lack evidence of renal amyloido-
sis; in contrast, mild forms of FMF may be complicated by
renal amyloidosis. The experience has been similar in other
conditions that lead to secondary amyloidosis. such as rheuma-
toid arthritis, osteomyelitis, and Hodgkin's disease. It would
appear that in the case of FMF, other factors besides the ethnic
background importantly influence the development of renal
amyloidosis.
With regard to the appropriate dose of colchicine for control-
ling the crises of FMF, it varies considerably in our experience
and in that of others. Only a fraction of the patients respond to a
daily dose of 0.5 mg, but approximately 90% respond to a dose
of 2.0 mg. It has been our practice to initiate treatment with 0.5
mg of colchicine daily and increase the dose by 0.5 mg up to 2.0
mg daily until we can control the crises. The required dose of
colchicine appears equally high in the pediatric population. In
the case of the patient under discussion, we administered a dose
as high as 3 mg daily.
Amyloid fibrils can be denatured by DMSO. I know of only
two patients with FMF-induced renal amyloidosis who received
DMSO treatment; the therapy was administered only after renal
insufficiency developed. There was no response to treatment
[601. I think, however, that more data on this mode of treatment
will be forthcoming.
DR. S0TIRI0U (Department of Pediatrics, Univ. of Thessalo-
niki Medical School, Thessaloniki): We have been caring for a
10-year-old girl with FMF. renal amyloidosis. and the nephrotic
syndrome. The crises started when she was approximately 8
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months old. She has had two abdominal operations and has had
episodes of monoarticular arthritis. We first saw her at the age
of 8 years. At that time the nephrotic syndrome was present and
the presence of renal amyloidosis was documented. Since then
she has been taking increasingly higher doses of coichicine—for
the last 16 months at a dose of 1.25 mg daily—and she continues
to experience crises of FMF; her nephrotic syndrome has
increased in severity but her renal function continues to be
normal.
DR. METAXAS: As I indicated, the dose of coichicine required
to control the attacks of FMF in children appears similar to that
in adults. Assuming that your patient is taking the medication, I
would suggest that you increase the dose further. I should point
out, however, that approximately 10% of the patients will not
respond to even a 2 mg daily dose of colchicine. Some other
patients may also continue to have an aborted form of crises
despite maximal colchicine dosage.
One should be particularly careful with the use of diuretics in
patients with renal amyloidosis, severe nephrotic syndrome, or
hypertension. It is my impression that injudicious diuresis in
such patients precipitates renal vein thrombosis.
DR. GEORGE SAKELLARIOU: (Renal Service, Second Depart-
ment of Propedeutic Medicine, Univ. of Thessaloniki Medical
School, Thessaloniki): I have two questions: First, what is the
role of colchicine in the prevention of recurrent amyloidosis
following renal transplantation? Second, why is arterial hyper-
tension so rare in patients with renal amyloidosis despite even
extensive parenchymal involvement?
DR. METAXAS: I strongly believe that patients with FMF and
renal amyloidosis who have undergone renal transplantation
should receive colchicine for the rest of their lives even though
no data currently suggest that such practice prevents redurrnt
amyloidosis. With regard to your second question, it is an old
observation that hypertension rarely occurs with renal amyloi-
dosis even in the presence of advanced renal failure. Adrenal
insufficiency had been implicated, but studies have shown that
the adrenal glands of such patients respond appropriately to
ACTH stimulation (28]. In my view, the relative absence of
hypertension is probably related to hypovolemia secondary to
the hypoalbuminemia of the nephrotic syndrome. It is also
possible that amyloid infiltration of the vessels might be respon-
sible. I should state, however, that the rarity of hypertension in
renal amyloidosis probably has been overemphasized in the
literature.
DR. MAIMAS: I also think that hypovolemia is probably an
important factor in the relative absence of hypertension in view
of the fact that these patients, like those with advanced diabetic
nephropathy, often continue to excrete large amounts of protein
in the urine even after end-stage renal failure develops. It has
been our experience, and that of others, that at least 30% of
patients with advanced amyloidosis have moderate hyperten-
sion, however [14, 61].
DR. AVRAAM AVRAMIDES (Endocrinology Department, Sec-
ond Department of Propedeutic Medicine, Univ. of Thessaloni-
ki Medical School, Thessaloniki): What are your recommenda-
tions about the use of chronic colchicine prophylaxis in view of
the potential hazard of azoospermia?
DR. METAXAS: As you know, instances of both azoospermia
[62] and aneuploidy [63] have been reported in patients taking
daily coichicine therapy, but vast experience suggests that
these occurrences must be very rare at the doses used for FMF
prophylaxis [64, 65]. Nevertheless, this matter is relevant when
one is dealing with individuals who desire to have children. It
has been my practice to advise such patients to discontinue the
medication 2 to 3 months before attempting to conceive.
DR. MADIAS: This particular issue has been addressed by
Wright and colleagues [66]. In a preliminary study, they have
shown that intermittent colchicine therapy—that is, short
courses of colchicine taken at the onset of the FMF attacks—
was effective in aborting the FMF crises. It would appear that
this therapeutic strategy deserves further investigation.
DR. MENELAOS PAPADIMITRIOU (Chief, Renal Service, Sec-
ond Department of Propedeutic Medicine, Univ. of Thessaloni-
ki Medical School, Thessaloniki): I should like to refer briefly to
the experience in using hemodialysis to treat patients who have
end-stage renal amyloidosis. Until about 5 years ago, hemodial-
ysis programs were reluctant to accept such patients, but this
policy has changed drastically. Berlyne has reported 10 patients
with renal amyloidosis who were treated with chronic hemodi-
alysis for a period of 3.5 to 5 years; the results failed to show
increased mortality or a higher rate of complications in these
patients as compared to the remainder of the authors' dialytic
population [28]. In a recent study by Rubinger et al [53],
hemodialysis appeared to ameliorate the clinical features of
FMF in a small group of patients. As Dr. Metaxas already has
pointed out, the European Dialysis and Transplant Association
has followed more than 700 patients with amyloidosis on
chronic hemodialysis [51]. The data indicate that these patients
have a 20% lower survival rate than do patients without
amyloidosis on chronic hemodialysis. Patients with amyloidosis
appear to have greater problems with vascular access because
of the poorer quality of their vessels and the greater tendency
for them to develop infectious complications. Progressive amy-
bid involvement of other organs is, of course, another factor
contributing to their limited survival. Infections and cardiac
complications appear to be the leading causes of death.
Forum commentary
KEITH P. W. J. MCADAM (Assistant Professor of Medicine,
Tufts University School of Medicine; and Experimental Medi-
cine Division, Department of Medicine, NEMC. Boston,
Mass.): Dr. Panagiotis Metaxas has reviewed most of the
clinical aspects of FMF and amyloidosis relevant to this very
interesting patient. I therefore shall focus on the current under-
standing of the pathogenesis of secondary amyloidosis and on
the proteins associated with the deposition of amyloid fibrils in
the tissues. Patients with secondary amyloidosis have in com-
mon a predisposing disease characterized by recurrent episodes
of fever and inflammation, with neutrophil leukocytosis and
elevation of the serum amyloid A protein (SAA) (67]. Familial
Mediterranean fever is an excellent example of such a disease,
but the coiditions causing secondary amyloidosis are quite
diverse in nature. They include chronic inflammatory diseases
such as rheumatoid arthritis and Crohn's disease, suppurative
diseases such as osteomyelitis and bronchiectasis, mycobacte-
rial diseases including lepromatous leprosy and tuberculosis,
and certain tumors such as Hodgkin's disease and renal carci-
noma. Although hypergammaglobulinemia is often present, the
major fibrillar protein isolated from organs infiltrated with
amyboid in these diseases is the amyloid A protein (AA). The
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amyloid A protein is distinct from the imunoglobulin light-chain
fragments that form the major fibril protein (AL) in patients
with plasma cell dyscrasias and in those with primary amyloido-
sis, i.e., those in whom no underlying cause can be identified.
Amyloid proteins of yet different chemical types have been
detected in familial Portuguese neuropathy, senile cardiac amy-
bid, and the endocrine tumor-associated amyloidosis such as
that occuring in medullary carcinoma of the thyroid [43].
An acute-phase reactant, the concentration of SAA rises
many hundredfold within a few hours of an inflammatory
stimulus [68]. In serurri, SAA circulates with high-density
lipoprotein [691, and it has been detected in at least 6 different
heterogeneous forms (SAA I through 6) [70]. The liver is the
major site of SAA synthesis [71, 72]. Recent in-vitro studies
have demonstrated synthesis of SAA in hepatocytes [73]. The
polymorphism of SAA in serum may reflect the ability of other
tissues, including neutrophils [74] and fibroblasts [75], to pro-
duce SAA. A soluble factor from monocytes provides the
trigger for acute-phase SAA synthesis [76]. The identity of this
SAA-stimulating factor is now known to be identical or very
similar to endogenous pyrogen and lymphocyte-activating fac-
tor [77]. Thus, purified endogenous pyrogen, produced by
activated macrophages, causes fever, stimulates hepatocytes to
synthesize SAA, and activates lymphocytes to proliferate. This
highly active molecule therefore may be the actual common
denominator among the several diseases that cause secondary
amyloidosis. It is noteworthy that patients with amyloidosis do
not appear to have a prolonged SAA response after an inflam-
matory stimulus (McAdam, Elm, Sipe, and Wolff, unpublished
observations).
Why only a minority of patients with chronic inflammatory
diseases develop amyloidosis is a central issue in amyloid
research. Elastase-type enzymes have been identified on the
monocyte membrane [78], in the serum [79], and within neutro-
phil lysosomes [801, which are capable of cleaving the 11,000 to
12,000 dalton SAA to a smaller AA-sized fragment (molecular
weight, 5000 to 8000). Thus, an enzyme deficiency in the
catabolic pathway of SAA could, in theory, predispose some
individuals to secondary amyloidosis. It is not clear whether
some SAA isotypes are more prone than others to form amyloid
fibrils. A nonfibrillar component, known as the pentagonal or
"P" component of amyloid (AP), has been found to coexist in
amyloid deposits irrespective of whether the chemical nature of
the amyloid fiber was AL, AA, or AMCT (amyloid in medullary
cell carcinoma of the thyroid). This component was first
detected by electron microscopy of amyloid deposits as a
pentagonal structure of outside diameter 90 A with an empty
inner core [81]. Antibodies to AP cross react with an alpha
globulin in normal human serum (SAP) [82—84]. Because Al'
and SAP have an identical structure, amino acid composition,
and sequence [85], they are thought to be composed of two
doughnut-like structures having 5 subunits of approximately
20,000 molecular weight each [86]. This protein is distinct from
SAA but has substantial sequence homology with C-reactive
protein (CRP), which also has a pentagonal tertiary structure
[87]. Although SAP is not an acute-phase protein in humans, it
is in mice [88], and it appears to be an integral part of the
glomerular basement membrane. Immunofluorescent studies
indicate increased concentrations of SAP in renal lesions asso-
ciated with a wide variety of nephropathies, including amyloid-
osis [89]. Although SAP binds to amyloid fibrils in a calcium-
dependent fashion [90], it is not clear whether its presence in
amyloid deposits reflects an "innocent bystander" role or
whether it acts as the "magnet" that attracts amyloid proteins
to the basement membrane. Other proteins including the calci-
um-dependent clotting factors X, IX, VII, and prothrombin also
bind to amyloid fibrils in vitro [91]. This accounts for the
occasional finding of a coagulopathy in patients harboring the
AL form of amyloid. Splenectomy reversed Factor X deficien-
cy in one patient with splenomegaly associated with AL [92].
When petechiae and ecchymoses occur, they generally reflect
an underlying capillary fragility.
Despite our greatly increased understanding of the pathogen-
esis of amyloidosis, there has been relatively little progress in
the clinical management of patients with this condition. Recent
clinical advances include the development of a rapid, simple
needle biopsy of abdominal wall subcutaneous fat [93]. This
technique is reported to be as reliable as rectal biopsy for
diagnosis of amyloidosis. In addition, it makes prevalence
studies of amyloidosis easier [94] and allows for relatively
noninvasive histologic sampling during treatment so that one
can assess the efficacy of therapy. Several different histologic
techniques have been developed to differentiate the chemical
varieties of amyloid. Deposits of AA are identified by their
sensitivity to proteolysis or potassium permanganate treatnient;
after such treatment, they fail to stain with Congo red [95].
Specific amyloid protein antisera are now available and have
permitted the utilization of immunofluorescent and immunoper-
oxidase testing [96].
Treatment of the underlying disease is of utmost imporlance
in the control of secondary amyloidosis. Colchicine has proved
highly effective in preventing painful attacks in FMF and in
reducing the incidence of amyloidosis in this disease. How it
does this is still unclear. Experimentally, colchicine prevents
the induction of amyloidosis in laboratory animals, In vitro,
colchicine prevents the secretion of SAA from the liver and
results in the accumulation of SAA within hepatocytes [72, 73].
Therapeutic doses of colchicine given to volunteers arid to
patients with amyloidosis reduce the SAA elevation caused by a
standard inflammatory stimulus by at least 50%. Dosages larger
than 0.5 mg three times a day generally cause diarrhea and are
not tolerated long.
Apart from colchicine, the only therapeutic agent reported to
be helpful in patients with secondary amyloidosis is DMSO.
This remarkable solvent has been tested as a prevention and a
treatment of AA disease experimentally [97, 98]. Anecdotal
case reports suggest cause for optimism in patients [99, 100],
although the usefulness of the drug is seriously impaired by the
permeating odor of the metabolic product, dimethyl sulphide,
which is excreted on the breath for up to 8 days following a
single dose. One report stated that DMSO caused increased
excretion of AA fibrils in the urine and suggested that reversal
of disease may be possible [101]. Any claims for successful
treatment of amyloidosis need to be interpreted with caution,
however, in view of the occasional, well-documented spontane-
ous remissions. Moreover, redistribution of amyloid deposits
from spleen and liver to the kidney following DMSO treatment
has been observed experimentally [102]. There is evidence that
biologic pathways do exist by which established amyloid depos-
its can be mobilized. Administration of colchicine and treat-
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ment of the underlying disease might prevent new fibril forma-
tion; under these circumstances, catabolic enzymes for the AA
protein, even if reduced, may be sufficient to clear the body of
its secondary amyloid deposits.
Reprint requests to Prof. P. Met taos, Second Department of Prope-
deutic Medicine University of Thessaloniki Medical School, Agia
Sophia Hospital, Thessaloniki, Greece
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